A small, pilot, randomised, cross over trial that investigates the potential for DPPIVi
therapy to reduce insulin requirements in type 1 diabetes was studied. We investigated
whether this drug reduces daily insulin doses, leads to weight reduction, reduces blood
glucose fluctuation and improves glucose control. Through reduction of blood glucose
variability, we want investigated, whether it has the capability of improving the magnitude
of epinephrine responses at 2.5mmol/L by performing a hyperinsulinaemic, hypoglycaemia clamp
study after each arm. A successful outcome would then lead to an application for funds for a
larger, multicentre intervention study. The benefits of this therapeutic advance are clear
and this has the potential to make a dramatic improvement to the lives of people with type 1
diabetes in our community.